Skip to content
EmbarkNeuro
About
About Us
Our Team
Board of Directors
Scientific Advisors
Our Science
Rooted in Biology
Publications & Presentations
Clinical Trials
News
Careers
Contact
News
Press Releases
November 21, 2022
EmbarkNeuro announces initiation of phase 2 trial of ANC-501, a first-in-class, V1b receptor antagonist for the personalized treatment of depression
November 8, 2021
Aditum Bio announces the appointment of Stephen Kanes, M.D. Ph.D., as Chief Executive Officer of Ancora Bio
June 30, 2021
Aditum Bio announces formation of Ancora Bio, to focus on treatment resistant depression
